A whale with a lot of money to spend has taken a noticeably bullish stance on CRISPR Therapeutics.
Looking at options history for CRISPR Therapeutics CRSP we detected 13 strange trades.
If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 46% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $109,793 and 10, calls, for a total amount of $480,415.
What's The Price Target?
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $45.0 to $75.0 for CRISPR Therapeutics over the last 3 months.
Volume & Open Interest Development
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for CRISPR Therapeutics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of CRISPR Therapeutics's whale trades within a strike price range from $45.0 to $75.0 in the last 30 days.
CRISPR Therapeutics Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| CRSP | CALL | SWEEP | BEARISH | 06/16/23 | $60.00 | $127.1K | 787 | 115 |
| CRSP | CALL | SWEEP | BULLISH | 07/21/23 | $65.00 | $66.9K | 747 | 191 |
| CRSP | PUT | SWEEP | BULLISH | 01/17/25 | $60.00 | $55.0K | 19 | 43 |
| CRSP | CALL | SWEEP | BEARISH | 07/21/23 | $65.00 | $41.1K | 747 | 140 |
| CRSP | CALL | TRADE | BULLISH | 07/21/23 | $60.00 | $40.5K | 850 | 55 |
Where Is CRISPR Therapeutics Standing Right Now?
- With a volume of 1,675,191, the price of CRSP is up 3.47% at $68.08.
- RSI indicators hint that the underlying stock may be overbought.
- Next earnings are expected to be released in 76 days.
What The Experts Say On CRISPR Therapeutics:
- RBC Capital downgraded its action to Sector Perform with a price target of $50
- Needham downgraded its action to Buy with a price target of $82
- Citigroup has decided to maintain their Neutral rating on CRISPR Therapeutics, which currently sits at a price target of $70.
- Credit Suisse has decided to maintain their Neutral rating on CRISPR Therapeutics, which currently sits at a price target of $62.
- Stifel has decided to maintain their Hold rating on CRISPR Therapeutics, which currently sits at a price target of $64.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for CRISPR Therapeutics, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
